Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27010171 | 0.86 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3HRH3KCNH2 | |
| SCHEMBL24317562 | 0.86 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3HRH3KCNH2 | |
| SCHEMBL26619696 | 0.86 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3HRH3KCNH2 | |
| SCHEMBL27010167 | 0.84 | HRH3 (0.41) | SLC6A2SLC6A4SLC6A3HRH3 | |
| SCHEMBL24317561 | 0.84 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3HRH3KCNH2 | |
| SCHEMBL24080124 | 0.81 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3HRH3KCNH2 | |
| SCHEMBL27010165 | 0.81 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3HRH3KCNH2 | |
| SCHEMBL27010174 | 0.78 | CHRM2 (0.39) | SLC6A2SLC6A3HRH3 | |
| SCHEMBL27010161 | 0.77 | SLC6A2 (0.38) | SLC6A2SLC6A3 | |
| SCHEMBL20068832 | 0.76 | HRH3 (0.50) | SLC6A2SLC6A4SLC6A3HRH3FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2022081925-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | SLC6A2 2569/4885SLC6A4 2521/4885SLC6A3 2302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.